SynthesisNeurosurgical review2026
Single-fraction stereotactic radiosurgery vs. hypofractionated stereotactic radiotherapy for resected brain metastases: a systematic review and meta-analysis of comparative studies.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative stereotactic radiotherapy (SRT) is widely used after resection of limited brain metastases, but the optimal fractionation remains uncertain. Single-fraction stereotactic radiosurgery (SF-SRS) is convenient and well established, whereas hypofractionated stereotactic radiotherapy (HF-SRT) may improve dose delivery and normal tissue tolerance in larger or more complex cavities. This systematic review and meta-analysis compared these two postoperative approaches. PubMed, Scopus, and Embase were searched from inception to December 23, 2025. Original comparative studies enrolling adults treated with postoperative cavity-directed stereotactic radiotherapy were included. Risk of bias was assessed using ROBINS-I. Seven retrospective comparative studies met the inclusion criteria, representing 589 patients and 649 resection cavities. The most common primary tumor was non-small cell lung cancer followed by melanoma and breast cancer. The RT dose in the single fraction population was between 15 and 20 Gy across the studies. Also, the hypofractionated regimen consisted of 3 to 6 fractions with the total dose being anywhere from 14 to 32.5 Gy. At 6 months, local control was marginally higher with SF-SRS than HF-SRT (RR 1.05, 95% CI 1.01-1.09, p = 0.006). However, given that HF-SRT was preferentially used for larger or anatomically complex cavities, this difference likely reflects baseline imbalances rather than a true treatment effect. The 12-month local control analysis showed a non-significant trend favoring SF-SRS (RR 1.06, 95% CI 0.99-1.14, p = 0.08). Three studies were pooled for 12-month overall survival, with no significant difference between approaches (RR 1.08, 95% CI 0.82-1.41, p = 0.59). The available comparative retrospective evidence suggests that SF-SRS and HF-SRT achieve broadly similar postoperative outcomes for resected limited brain metastasis although HF-SRT cohorts included larger or deeply seated lesions. Nevertheless, SF-SRS may offer a small early local control advantage. Prospective randomized studies are needed to define the optimal postoperative strategy.
Indexed as
Identifiers
42700305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.